UPDATE 1-Merck clot drug meets study goal but bleeding a risk
February 07, 2012 at 08:59 AM EST
Feb 7 (Reuters) - Merck & Co's experimental anti-clotting drug vorapaxar met the main goal of significantly reducing a host of cardiovascular problems in a large clinical study, but raised the risk of bleeding, the drugmaker said on Tuesday.